diclofenamide
Approved
Jul 22, 1958
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown. — NCATS
Clinical trial activity
2 trials · 4 clinical orgs · 5 marketing orgs
Earliest trial started Jun 1, 1992 (NCT00004802)
Timeline
1950s
- Jul 22, 1958
Merck — Earliest FDA Approval
- Jul 22, 1958
Strongbridge Biopharma — NDA Secondary Org
- Jul 22, 1958
Merck — NDA Organization
- Jul 22, 1958
Xeris Pharmaceuticals — Marketing Organization
- Jul 22, 1958
Xeris Pharmaceuticals — NDA Secondary Org
1990s
- Jan 1, 1992
Earliest Phase 3 Sponsor(trial)
2020s
- Dec 29, 2022
Torrent Pharmaceuticals Limited — Marketing Organization
- Nov 18, 2025
Rising Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Carbonic anhydrase XIIINHIBITOR
CA12 inhibitor
- Carbonic anhydrase IINHIBITOR
CA1 inhibitor
- Carbonic anhydrase IVINHIBITOR
CA4 inhibitor
- Carbonic anhydrase IIINHIBITOR
CA2 inhibitor
Approval history
- approvedJul 22, 1958
Chemistry & pharmacology
SMILES
NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O- Mol. weight
- 305.159 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDiclofenamide ↗
- NCATSVVJ6673MHY ↗
- ChEMBLCHEMBL17 ↗
- ChEMBLCHEMBL1515611 ↗
Also known as
- 1,3-disulfamoyl-4,5-dichlorobenzene
- 1,3-disulfamoyl-4,5-dichlorobenzene
- 1,3-disulfamyl-4,5-dichlorobenzene
- 1,3-disulfamyl-4,5-dichlorobenzene
- 3,4-dichloro-5-sulfamylbenzenesulfonamide
- 3,4-dichloro-5-sulfamylbenzenesulfonamide
- 4,5-dichloro-1,3-benzenedisulfonamide
- 4,5-dichloro-1,3-benzenedisulfonamide
- 4,5-dichloro-1,3-disulfamoylbenzene
- 4,5-dichloro-1,3-disulfamoylbenzene
- 4,5-dichlorobenzene-1,3-disulfonamide
- 4,5-dichlorobenzene-1,3-disulfonamide
- 4,5-dichloro-benzene-1,3-disulfonic acid diamide
- 4,5-dichloro-benzene-1,3-disulfonic acid diamide
- 4,5-dichloro-m-benzenedisulfonamide
- 4,5-dichloro-m-benzenedisulfonamide
- daranide
- daranide
- daranide
- dichlofenamide
- dichlofenamide
- dichlofenamide
- dichlorophenamide
- dichlorophenamide
- dichlorophenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- dichlorphenamide
- diclofenamid
- diclofenamida
- diclofenamida
- diclofenamide
- diclofenamide
- diclofenamide
- diclofenamide
- diclofenamide
- diclofenamide
- diclofenamide
- diclofenamidum
- diclofenamidum
- glaucol
- oratrol
- oratrol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00494507 | Phase 3 | Jun 1, 2007 | National Institute of Neurological Disorders and Stroke (NINDS), University of Rochester |
| NCT00004802 | Phase 3 | Jun 1, 1992 | National Center for Research Resources (NCRR), Ohio State University |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Center for Research Resources (NCRR) | Government | 1 | 1 | 1 | 1992 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2007 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 1992 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2007 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Merck | For profit | NDA | Jul 22, 1958 |
| Rising Pharmaceuticals | For profit | MKTG | Nov 18, 2025 |
| Strongbridge Biopharma | For profit | NDA2 | Jul 22, 1958 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Dec 29, 2022 |
| Xeris Pharmaceuticals | For profit | MKTG | Jul 22, 1958 |
| Xeris Pharmaceuticals | For profit | NDA2 | Jul 22, 1958 |